ERT to Acquire PHT Corporation
ERT, a leading global solution provider for high- quality patient safety and efficacy endpoint data collection, and PHT Corporation (PHT), the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced today that they have signed a definitive agreement under which ERT will acquire PHT.
ERT, a global solutions provider for high-quality patient safety and efficacy endpoint data collection, and PHT Corporation (PHT), an eClinical provider leading the adoption of patient?driven mobile apps, announced today that they have signed a definitive agreement under which ERT will acquire PHT. Financial terms of the transaction were not disclosed. The transaction combines the flexible PHT eCOA platform with the leading clinical trial technology and service offerings of ERT, creating a comprehensive solution for patient endpoint collection and data analytics for global clinical trials.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
